HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AP23464

a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleotides: 140
        Adenine Nucleotides: 1066
        Adenosine Triphosphate: 27668
        AP23464: 3
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Ribonucleotides: 307
    - Adenine Nucleotides: 1066
      - Adenosine Triphosphate: 27668
        AP23464: 3
  - Purine Nucleotides: 140
    - Adenine Nucleotides: 1066
      - Adenosine Triphosphate: 27668
        AP23464: 3

Experts

1.	Dalgarno, David: 2 articles (01/2006 - 07/2005)
2.	Sundaramoorthi, Raji: 2 articles (01/2006 - 07/2005)
3.	Wang, Yihan: 2 articles (01/2006 - 07/2005)
4.	Gotlib, Jason: 1 article (08/2006)
5.	Adams, Susan: 1 article (01/2006)
6.	Andrade, Lawrence: 1 article (01/2006)
7.	Bohacek, Regine: 1 article (01/2006)
8.	Grossman, Trudy: 1 article (01/2006)
9.	Jin, Lei: 1 article (01/2006)
10.	Keats, Jeff: 1 article (01/2006)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2005 - "Thus, AP23464 and AP23848 potently and selectively target activation-loop mutants of Kit in vitro and in vivo and could have therapeutic potential against D816V-expressing malignancies." 01/01/2006 - "Here, we present crystal structures of the kinase domain of Src in complex with two purine-based inhibitors: AP23451, a small-molecule inhibitor designed to inhibit Src-dependent bone resorption, and AP23464, a small-molecule inhibitor designed to inhibit the Src-dependent metastatic spread of cancer. "
2.	Mastocytosis 08/01/2006 - "Perhaps the most important development in this era of targeted therapy, and certainly relevant to KIT-driven diseases like mastocytosis, is the realization that small molecule inhibitors with varied chemical structure (eg, PKC412, dasatinib, AP23464) can circumvent the resistance of TKs to first-generation agents such as imatinib. "
3.	Bone Resorption 01/01/2006 - "Here, we present crystal structures of the kinase domain of Src in complex with two purine-based inhibitors: AP23451, a small-molecule inhibitor designed to inhibit Src-dependent bone resorption, and AP23464, a small-molecule inhibitor designed to inhibit the Src-dependent metastatic spread of cancer. "

Related Drugs and Biologics

1.	AP23848
2.	Phosphotransferases (Kinase)
3.	Dasatinib (BMS 354825)
4.	Imatinib Mesylate (Gleevec)
5.	AP 23451
6.	midostaurin
7.	purine

Related Therapies and Procedures

1.	Therapeutics